Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials  by unknown
Articles
www.thelancet.com   Vol 378   November 12, 2011 1707
Lancet 2011; 378: 1707–16
Published Online
October 20, 2011
DOI:10.1016/S0140-
6736(11)61629-2
See Comment page 1680
*Collaborators listed in Articles 
Lancet 2011; 378: 771–84 and 
webappendix p 48
Correspondence to:
EBCTCG Secretariat, 
Clinical Trial Service Unit (CTSU), 
Richard Doll Building, 
Oxford OX3 7LF, UK
bc.overview@ctsu.ox.ac.uk
Eﬀ ect of radiotherapy after breast-conserving surgery on 
10-year recurrence and 15-year breast cancer death: 
meta-analysis of individual patient data for 10 801 women 
in 17 randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*
Summary
Background After breast-conserving surgery, radiotherapy reduces recurrence and breast cancer death, but it may do 
so more for some groups of women than for others. We describe the absolute magnitude of these reductions according 
to various prognostic and other patient characteristics, and relate the absolute reduction in 15-year risk of breast 
cancer death to the absolute reduction in 10-year recurrence risk. 
Methods We undertook a meta-analysis of individual patient data for 10 801 women in 17 randomised trials of 
radiotherapy versus no radiotherapy after breast-conserving surgery, 8337 of whom had pathologically conﬁ rmed 
node-negative (pN0) or node-positive (pN+) disease. 
Findings Overall, radiotherapy reduced the 10-year risk of any (ie, locoregional or distant) ﬁ rst recurrence from 35·0% 
to 19·3% (absolute reduction 15·7%, 95% CI 13·7–17·7, 2p<0·00001) and reduced the 15-year risk of breast cancer 
death from 25·2% to 21·4% (absolute reduction 3·8%, 1·6–6·0, 2p=0·00005). In women with pN0 disease (n=7287), 
radiotherapy reduced these risks from 31·0% to 15·6% (absolute recurrence reduction 15·4%, 13·2–17·6, 2p<0·00001) 
and from 20·5% to 17·2% (absolute mortality reduction 3·3%, 0·8–5·8, 2p=0·005), respectively. In these women 
with pN0 disease, the absolute recurrence reduction varied according to age, grade, oestrogen-receptor status, 
tamoxifen use, and extent of surgery, and these characteristics were used to predict large (≥20%), intermediate 
(10–19%), or lower (<10%) absolute reductions in the 10-year recurrence risk. Absolute reductions in 15-year risk of 
breast cancer death in these three prediction categories were 7·8% (95% CI 3·1–12·5), 1·1% (–2·0 to 4·2), and 0·1% 
(–7·5 to 7·7) respectively (trend in absolute mortality reduction 2p=0·03). In the few women with pN+ disease 
(n=1050), radiotherapy reduced the 10-year recurrence risk from 63·7% to 42·5% (absolute reduction 21·2%, 95% CI 
14·5–27·9, 2p<0·00001) and the 15-year risk of breast cancer death from 51·3% to 42·8% (absolute reduction 8·5%, 
1·8–15·2, 2p=0·01). Overall, about one breast cancer death was avoided by year 15 for every four recurrences avoided 
by year 10, and the mortality reduction did not diﬀ er signiﬁ cantly from this overall relationship in any of the three 
prediction categories for pN0 disease or for pN+ disease. 
Interpretation After breast-conserving surgery, radiotherapy to the conserved breast halves the rate at which the 
disease recurs and reduces the breast cancer death rate by about a sixth. These proportional beneﬁ ts vary little 
between diﬀ erent groups of women. By contrast, the absolute beneﬁ ts from radiotherapy vary substantially 
according to the characteristics of the patient and they can be predicted at the time when treatment decisions need 
to be made. 
Funding Cancer Research UK, British Heart Foundation, and UK Medical Research Council.
Introduction
For many women with early-stage breast cancer, breast-
conserving surgery can remove any macroscopic disease 
that has been detected; however, some microscopic 
tumour foci might remain in the conserved breast that 
could, if untreated, lead to locoregional recurrence or 
life-threat ening distant metastases, or both. This report 
up dates previous analyses from the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) of individual 
patient data from the randomised trials of radiotherapy 
after breast-conserving surgery.1–5 It includes further 
follow-up for nine of the ten trials analysed previously;5 
adds data from seven new trials, six of which were in 
low-risk women; and increases the total number of 
women analysed by nearly 50%. The report focuses 
mainly on women for whom pathological axillary lymph 
node status is known (negative [pN0] or positive [pN+]), 
because such information is usually available nowadays. 
It assesses the extent to which the radiotherapy-related 
absolute reduction in 10-year risk of ﬁ rst recurrence at 
any site (locoregional or distant) varies for women with 
diﬀ erent prognostic and other factors. It then relates 
the absolute reduction in the 15-year risk of breast 
cancer death to the absolute reduction in the 10-year 
risk of a recurrence.
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Methods
Study design
Eligible trials were those beginning before the year 
2000 of adjuvant radiotherapy versus no radiotherapy 
following breast-conserving surgery for invasive cancer. 
Trial identiﬁ cation and data handling were as previously 
reported.5 For every woman, information was sought 
regarding initial characteristics, allocated treatment, time 
to ﬁ rst recurrence, whether the ﬁ rst recurrence was 
locoregional or distant (excluding contra lateral breast 
cancer), and date last known alive or date and underlying 
cause of death. When no recurrence was reported before 
breast cancer death, distant recurrence was assumed to 
have just preceded it. If contralateral breast cancer 
occurred before any other recurrence, follow-up was 
censored on that date in recurrence analyses. 
Statistical analysis
The method used in this study diﬀ ers from that used 
previously.5 First, to avoid assumptions about how 
locoregional and distant recurrence relate to each other, 
the main emphasis is on analyses of any ﬁ rst recurrence 
rather than, as before, of time to locoregional recurrence 
as a ﬁ rst event. Second, most analyses of recurrence 
present data for only 10 years, because many of these trials 
did not follow up women beyond this time for recurrence. 
This absence of follow-up should not bias the estimated 
proportional eﬀ ect on recurrence after year 10, but could 
aﬀ ect estimates of the absolute recurrence risk after 
year 10 substantially. Third, deaths of unknown cause 
before recurrence are no longer attributed to breast cancer, 
because most occurred many years after trial entry, by 
which time non-breast-cancer mortality predominated. 
Other aspects of the methods used are as before.5 Log-rank 
analyses are stratiﬁ ed by trial, individual follow-up year, 
and nodal status. They are also stratiﬁ ed by age, either in 
ﬁ ve groups (<40, 40–49, 50–59, 60–69, 70+ years) or, when 
data are also subdivided by other factors, in two groups 
(<50 and 50+ years).
Analyses of the dependence of absolute risk, and 
absolute risk reduction, on several factors simultaneously 
use Poisson regression ﬁ tted by maximum likelihood 
(webappendix pp 20–25). In these analyses absolute risk 
of any ﬁ rst recurrence is adjusted for trial, individual 
follow-up year, nodal status, and age (ﬁ ve groups), and 
also for tumour grade, tumour size, oestrogen-receptor 
(ER) status, and whether or not tamoxifen had been 
used in both randomised groups in the trial.
Preliminary results were presented to collaborators 
in September, 2010. A report was circulated to collabor-
ators for comment in January, 2011, and then 
revised centrally.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The Secretariat had full access to all 
data and analyses. Submission for publication was 
decided only by the writing committee.
Results
Information was available for 10 801 women in 17 trials 
(table 1). Six trials were of radiotherapy after lumpec-
tomy and included both low-risk and high-risk women 
Number 
of trials 
available*
Years 
trials 
began
Women Deaths Woman-years at risk
Median/
woman
Total 
(thousands)
Distribution by years since diagnosis 
(thousands)
<5 5–9 10–14 15–19 20+
Trial category†
(A) Lumpectomy, original trials6–11 6 1976–86 4398 1982 11·8 52·9 20·3 16·0 10·1 4·8 1·7
(B) Sector resection or quadrantectomy12–15 4 1981–91 2399 708 12·4 29·4 11·6 10·3 6·0 1·4 0·1
(C) Lumpectomy in low-risk women16–22 7 1989–99 4004 453 6·6 26·9 17·9 7·9 1·1 0·0 0·0
Pathological nodal status
Negative (pN0) .. .. 7287 1801 9·7 73·7 34·0 23·3 11·3 3·9 1·2
Positive (pN+) .. .. 1050 585 10·3 11·8 4·6 3·2 2·2 1·3 0·5
Unknown .. .. 2464 757 8·8 23·6 11·3 7·6 3·7 1·0 0·0
All women 17 1976–99 10 801 3143 9·5 109·1 49·8 34·1 17·2 6·3 1·7
*Only unconfounded trials are considered—ie, trials in which there was no diﬀ erence between the treatment groups in the type or extent of surgery or in the use of systemic 
therapy. Two further eligible trials,23,24 both category A with a total of 133 women, were identiﬁ ed but data were unavailable. Details of the 17 available trials are given in 
webappendix pp 4, 45–47. †Elsewhere, these trial categories are abbreviated to: (A) Lumpectomy: original; (B) >Lumpectomy; (C) Lumpectomy: low risk. In category A, 
55% were pathologically node negative, 5% were aged 70+ years, 10% had low-grade tumours, 54% had T1 tumours (1–20 mm), 81% had oestrogen-receptor (ER)-positive 
disease or unknown status, and 44% were in trials in which tamoxifen was used in both trial groups. In category B, 81% were pathologically node negative, 10% were aged 
70+ years, 9% had low-grade tumours, 89% had T1 tumours, 86% had ER positive disease or unknown status, and 6% were in trials in which tamoxifen was used in both trial 
groups. In category C, 73% were pathologically node negative, 40% were aged 70+ years, 33% had low-grade tumours, 90% had T1 tumours, 98% had ER positive disease or 
unknown status, and 88% were in trials in which tamoxifen was used in both trial groups. 
Table 1: Availability of data from randomised trials of radiotherapy after breast-conserving surgery for invasive cancer that began before the year 2000 
See Online for webappendix
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(category A, 4398 women), four were of radiotherapy 
after sector resection or quadrantectomy (category B, 
2399 women), and seven more recent trials were of 
radiotherapy after lumpectomy in low-risk women 
(category C, 4004 women). In most of the trials 
radiotherapy was to the conserved breast only 
(webappendix p 4). Median follow-up was 9·5 years at 
risk per woman and 25% of women were followed up 
for more than a decade. 3143 (29%) had died by the ﬁ nal 
follow-up date of Sept 30, 2006.
The 10-year risk of any (locoregional or distant) ﬁ rst 
recurrence was 19·3% in women allocated to radiotherapy 
and 35·0% in women allocated to breast-conserving 
surgery only, corresponding to an absolute risk reduction 
of 15·7% (95% CI 13·7–17·7, 2p<0·00001; ﬁ gure 1). 
Nearly three-quarters of ﬁ rst recurrences in the no 
radiotherapy group were locoregional (25% locoregional 
ﬁ rst, 10% distant ﬁ rst), compared with fewer than half of 
those in the radiotherapy group (8% locoregional ﬁ rst, 
12% distant ﬁ rst; webappendix p 9). In addition to 
reducing recurrence substantially, radiotherapy also 
reduced breast cancer death by a moderate amount: the 
15-year absolute risk reduction was 3·8% (95% CI 
1·6–6·0, 2p=0·00005), suggesting on average about one 
breast cancer death avoided for every four recurrences 
avoided by radiotherapy.
Allocation to radiotherapy halved the average annual 
rate of any ﬁ rst recurrence (rate ratio [RR] 0·52, 95% CI 
0·48–0·56, ﬁ gure 1). The proportional reduction was 
greatest in the ﬁ rst year (0·31, 0·26–0·37), but was still 
substantial during years 5–9 (0·59, 0·50–0·70; web-
appendix p 13). Beyond year 10 there was no evidence of 
any further eﬀ ect on the ﬁ rst recurrence rate, but 
information about recurrence in this period was 
incomplete so the number of events was small and the 
CI wide (ﬁ gure 1). Radiotherapy reduced the annual 
breast cancer death rate by a sixth (RR 0·82, 0·75–0·90). 
The timing of breast cancer death diﬀ ered from that of 
ﬁ rst recurrence, with few events during the ﬁ rst year 
(ﬁ gure 1), and there were substantial numbers of breast 
cancer deaths after year 10.
Mortality without recurrence from non-breast-cancer 
causes was slightly higher in women allocated to radio-
therapy than in women allocated to breast-conserving 
Figure 1: Eﬀ ect of radiotherapy (RT) after breast-conserving surgery (BCS) on 10-year risk of any (locoregional or distant) ﬁ rst recurrence and on 15-year risks 
of breast cancer death and death from any cause in 10 801 women (67% with pathologically node-negative disease) in 17 trials
Further details are in webappendix p 5. RR=rate ratio. Rate ratios in this ﬁ gure include all available years of follow-up.
Figure 2: Eﬀ ect of radiotherapy (RT) after breast-conserving surgery (BCS) on 10-year risk of any 
(locoregional or distant) ﬁ rst recurrence and on 15-year risk of breast cancer death in women with 
pathologically veriﬁ ed nodal status
Vertical lines indicate 1 SE above or below the 5, 10, and 15 year percentages. Further details are in webappendix 
pp 6–7. pN0=pathologically node-negative. pN+=pathologically node-positive. RR=rate ratio. Rate ratios in this 
ﬁ gure include all available years of follow-up.
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surgery only, but the excess was not signiﬁ cant (RR 1·09, 
95% CI 0·97–1·22, 2p=0·14). If the mortality rate from 
non-breast-cancer causes in women allocated to radio-
therapy had been identical to that in women allocated 
to breast-conserving surgery only, then the 15-year 
absolute risk reduction in all-cause mortality would 
have been 3·2%. In fact, the 15-year absolute risk 
reduction in all-cause mortality was 3·0% (95% CI 
0·6–5·4, 2p=0·03; ﬁ gure 1). 
Most women (n=7287) had pN0 disease. In this group, 
allocation to radiotherapy halved the average annual 
recurrence rate during the ﬁ rst decade (RR 0·46, 95% CI 
0·41–0·51), reducing the 10-year risk of any ﬁ rst 
recurrence from 31·0% to 15·6%, an absolute reduction 
of 15∙4% (95% CI 13·2–17·6, 2p<0∙00001  ﬁ gure 2). For 
these women, radiotherapy reduced breast cancer death 
by about a sixth (RR 0·83, 95% CI 0·73–0·95), and 
reduced the 15-year risk of breast cancer death from 
20·5% to 17·2%, an absolute reduction of 3·3% (95% CI 
0·8–5·8, 2p=0∙005; ﬁ gure 2).
For the 1050 women with pN+ disease, allocation to 
radiotherapy reduced the 1-year recurrence risk from 
Figure 3: Event rates for any (locoregional or distant) ﬁ rst recurrence (% per year) and recurrence rate ratios for various factors, considered separately, during 
years 0–9 in women with pathologically node-negative disease (n=7287)
BCS=breast-conserving surgery. RT=radiotherapy. ER=oestrogen receptor. Categories including unknowns excluded from tests for trend and heterogeneity. †A trial policy 
of tamoxifen use gives tamoxifen to both treatment groups if the disease is ER positive (or ER unknown, here counted with ER positive); additional therapy could be 
chemotherapy (usually cyclophosphamide, methotrexate, ﬂ uorouracil [CMF]) for both treatment groups, or additional RT (nodal RT or a boost or both) for those 
allocated BCS+RT. ‡Deﬁ nitions of trial categories A, B, and C are in table 1. Further details are in webappendix p 14. 
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26·0% to 5·1%, which is a ﬁ ve-fold reduction (RR 0·20, 
95% CI 0·14–0·29). There was a moderate additional eﬀ ect 
over the next few years but little further eﬀ ect after year 5 
(ﬁ gure 2). When these very diﬀ erent proportional eﬀ ects 
in diﬀ erent periods since treatment were combined, the 
mean annual recurrence rate during the whole of the ﬁ rst 
decade was halved in pN+ disease (RR 0·50, 95% CI 
0·41–0·61). Although the proportional reductions in the 
mean annual recurrence rate were similar in pN0 and 
pN+ disease, the absolute 10-year recurrence reduction 
seemed to be somewhat larger in pN+ disease at 21·2% 
(95% CI 14·5–27·9, 2p<0·00001, 42·5% vs 63·7%). 
Radiotherapy also reduced breast cancer death in 
pN+ disease (RR 0·79, 95% CI 0·65–0·95, 2p=0·01), with 
a 15-year absolute reduction of 8·5% (95% CI 1·8–15·2; 
42·8% vs 51·3%).  
In both pN0 and pN+ disease, the ﬁ rst recurrence was 
locoregional for a higher proportion of women allocated 
to breast-conserving surgery only than of women allo-
cated to breast-conserving surgery plus radiotherapy 
(web appendix p 10).
Analyses of the eﬀ ects of treatment in various subgroups 
of women with pN0 disease are much more likely to 
identify diﬀ erences reliably if they are based on recurrence 
than on mortality, because the signiﬁ cance level of the 
eﬀ ect of radiotherapy is much more extreme for 
recurrence than for mortality (2p<0·00001 for recurrence 
[χ²₁=209·0], 2p=0·005 for breast cancer death [χ²₁=7·8]).
Number 
allocated 
BCS+RT/BCS
10-year risk of a locoregional or distant recurrence (%) Test for trend/heterogeneity in absolute 
reduction
BCS+RT BCS Absolute reduction 
with RT (95% CI)
2p unadjusted* 2p adjusted*
(a) Entry age (years) <0·00001 0·0002
<40 189/174 36·1 60·7 24·6 (13·2 to 36·0)
40–49 576/582 20·8 41·4 20·6 (15·1 to 26·1)
50–59 1093/1028 15·0 29·7 14·7 (10·8 to 18·6)
60–69 1138/1167 14·2 28·3 14·1 (10·4 to 17·8)
70+ 679/661 8·8 17·7 8·9 (4·0 to 13·8)
(b) Tumour grade <0·00001 <0·00001
Low 750/757 11·0 22·4 11·4 (6·3 to 16·5)
Intermediate 816/843 16·4 31·6 15·3 (10·4 to 20·2)
High 448/431 28·6 53·3 24·7 (17·6 to 31·8)
Grade unknown 1661/1581 14·7 28·2 13·5 (10·4 to 16·6)
(c) Tumour size 0·02 0·06
T1 (1–20 mm) 2942/2920 12·4 27·5 15·1 (12·7 to 17·5)
T2 (21–50 mm) 513/487 30·7 50·0 19·3 (12·6 to 26·0)
Various/unknown 220/205 24·9 32·6 7·6 (–1·8 to 17·0)
(d) ER status and trial policy of tamoxifen use† <0·00001 0·003
ER-poor 448/427 28·9 43·8 14·9 (8·0 to 21·8)
ER-positive no tamoxifen 1686/1626 18·6 36·0 17·4 (14·3 to 20·5)
ER-positive with tamoxifen 1541/1559 8·7 22·0 13·3 (10·0 to 16·6)
(e) Trial policy of using additional therapy† 0·06 0·45
No 1498/1471 15·8 31·6 15·8 (12·7 to 18·9)
Yes 2127/2085 16·1 31·8 15·6 (12·3 to 18·9)
Some/unknown 50/56 ·· ·· ··
(f) Trial category‡ <0·00001 (A vs C);
0·90 (A+C vs B)
0·16 (A vs C);
0·00003 (A+C vs B)
(A) Lumpectomy: original 1223/1197 27·8 47·9 20·1 (16·0 to 24·2)
(B) >Lumpectomy 986/970 14·3 25·9 11·6 (7·9 to 15·3)
(C) Lumpectomy: low risk 1466/1445 6·3 19·9 13·6 (9·7 to 17·5)
Total 3675/3612 15·6 31·0 15·4 (13·2 to 17·6)
Information about numbers of events and woman-years is in webappendix p 26. Results for 5-year risks are in webappendix p 31. ER=oestrogen receptor. *Unadjusted: each 
factor alone. Adjusted: each factor adjusted for all other factors by means of regression modelling. Categories including unknowns excluded from test for trend or 
heterogeneity. †A trial policy of tamoxifen use gives tamoxifen to both treatment groups if the disease is ER positive (or ER unknown, here counted with ER positive); 
additional therapy could be chemotherapy (usually cyclophosphamide, methotrexate, ﬂ uorouracil [CMF]) for both treatment groups, or additional RT (nodal RT or a boost or 
both) for those allocated BCS+RT. ‡Deﬁ nitions of trial categories A, B, and C are in table 1. 
Table 2: Eﬀ ect of radiotherapy (RT) after breast-conserving surgery (BCS) on 10-year risk of any (locoregional or distant) ﬁ rst recurrence in women with 
pathologically node-negative disease (n=7287), subdivided by patient and trial characteristics 
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In a series of analyses which focus ﬁ rst on proportional 
and then on absolute reductions in recurrence, women 
were subdivided into diﬀ erent groups to ascertain 
whether some groups beneﬁ t more than others from 
radiotherapy. In the ﬁ rst analysis, the proportional eﬀ ect 
of radiotherapy on the rate of any ﬁ rst recurrence in 
pN0 disease during the ﬁ rst 10 years was estimated for 
each of several factors considered separately (ﬁ gure 3). In 
most subgroups, radiotherapy roughly halved the annual 
recurrence rate (except that among women who had been 
given lump ectomy the proportional recurrence reduction 
was some what less extreme in ER-poor disease [2p=0·01, 
section (d) of ﬁ gure 3] and somewhat more extreme in 
the low-risk [category C] trials [2p=0·009, section (f) of 
ﬁ gure 3]).
Halving a big risk produces a bigger absolute beneﬁ t 
than halving a small risk. In women with pN0 disease, 
the annual recurrence rate without radiotherapy was 
strongly correlated with age (inversely), tumour grade, 
tumour size, ER status (especially when tamoxifen was 
Figure 4: Absolute 10-year risks (%) of any (locoregional or distant) ﬁ rst recurrence with and without radiotherapy (RT) following breast-conserving surgery 
(BCS) in pathologically node-negative women by patient and trial characteristics, as estimated by regression modelling of data for 7287 women
Further details are in webappendix pp 27–30. Results for 5-year risks are in webappendix pp 31–34. Bars show 10-year risks in women allocated to BCS only, dark 
sections show 10-year risks in women allocated to BCS plus RT, light sections show absolute reduction with RT. ER=oestrogen receptor.
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used in ER-positive disease), and extent of surgery 
(inversely). The absolute recurrence reduction produced 
by radiotherapy also depended strongly on these factors 
(table 2). In the second analysis, the way in which the 
absolute reduction in 10-year recurrence risk produced 
by radiotherapy depended on all the potential explanatory 
factors listed in table 2 considered together was modelled. 
The modelling was carried out by considering information 
both for women allocated to radiotherapy and for those 
allocated to no radiotherapy (webappendix pp 20–25 
shows methodological details). 
The absolute recurrence reduction produced by 
radiotherapy and the absolute recurrence risk remaining 
even with radiotherapy varied signiﬁ cantly with age, 
tumour grade, ER status, and tamoxifen use, even after 
adjustment for all other factors (table 2). Tumour size 
was independently predictive of absolute recurrence risk 
although not of the absolute risk reduction.
When the original trials with lumpectomy (category A) 
and the later trials with lumpectomy in low-risk women 
(category C) were compared, there was a substantial 
diﬀ erence in the absolute recurrence risk without 
radiotherapy and in the absolute reduction in this risk 
produced by radiotherapy, but these diﬀ erences were 
largely accounted for by the other recorded factors 
(table 2; webappendix pp 15–17, 19).
Surgery that is more extensive than lumpectomy (as in 
the category B trials) reduced the absolute recurrence 
risk without radiotherapy and reduced the absolute 
reduction in this risk produced by radiotherapy. However, 
because the category B trials did not give tamoxifen, this 
eﬀ ect of the extent of surgery on the absolute eﬀ ect of 
radiotherapy was apparent only after adjustment for 
tamoxifen use (and the other recorded factors), but not 
before (table 2; webappendix p 18).
The characteristics that were independently predictive 
of the absolute risk of recurrence, or of the absolute risk 
reduction with radiotherapy, were included in a model to 
show how 10-year recurrence risks with and without 
radiotherapy depended in these trials on age, grade, 
ER status, tamoxifen (which was given much more often 
in the recent category C trials of low-risk patients than in 
the original category A trials), and extent of surgery. 
Figure 4 shows estimates based on this model. Within 
each section of the ﬁ gure, younger women and those 
with high-grade tumours had substantially larger absolute 
recurrence risks without radiotherapy and substantially 
larger absolute risk reductions with radiotherapy than 
did older women and those with low-grade tumours 
(ﬁ gure 4). Among women given lumpectomy but not 
radiotherapy, for a speciﬁ c age and grade, the highest 
risks and largest absolute reductions with radiotherapy 
were for women with ER-positive disease not given 
tamoxifen; however, even with tamoxifen the additional 
eﬀ ects of radiotherapy were substantial for women 
with high-grade tumours and younger women with 
intermediate-grade tumours (ﬁ gure 4). 
Each woman with pN0 disease was assigned a predicted 
absolute reduction in 10-year recurrence risk from radio-
therapy on the basis of her individual characteristics, the 
characteristics of the trial that she was in, and the model-
based estimates in ﬁ gure 4. The absolute reduc tion in 
10-year recurrence risk was large (≥20%) for 1924 women 
(56% of women in trial category A, 16% of trial category B, 
and 9% of trial category C), intermediate (10–19%) for 
3763 women (32%, 74%, and 53% of trial categories A, B, 
and C respectively), and lower (<10%) for 1600 women 
(12%, 10%, and 38% of trial categories A, B, and C 
respectively). For these three groups (pN0-lower, pN0-
intermediate, and pN0-large), the observed 10-year 
recurrence risks with and without radiotherapy, calcu-
lated directly from data for individual women, were 
26∙0% versus 50∙3% (absolute reduction of 24∙3%, 
95% CI 19∙6–29∙0), 12∙4% versus 24∙8% (absolute reduc-
tion of 12∙4%, 9∙7–15∙1), and 12∙0% versus 18∙9% 
(absolute reduction of 6∙9%, 2∙2–11∙6), respectively. The 
corres ponding absolute reductions in 15-year risk of 
breast cancer death in the three groups were 7·8% 
(95% CI 3·1–12·5), 1·1% (–2·0 to 4·2), and 0·1% 
(–7·5 to 7·7), respectively (trend in absolute mortality 
reduction: 2p=0·03; ﬁ gure 5, webappendix pp 35–37). 
For all three groups, the ﬁ rst recurrence was locoregional 
for a much larger proportion of women allocated to 
Figure 5: Absolute reduction in 15-year risk of breast cancer death with 
radiotherapy (RT) after breast-conserving surgery versus absolute reduction 
in 10-year risk of any (locoregional or distant) recurrence
Women with pN0 disease are subdivided by the predicted absolute reduction in 
10-year risk of any recurrence suggested by regression modelling (pN0-large 
≥20%, pN0-intermediate 10–19%, pN0-lower <10%; further details are in 
webappendix pp 35–39). Vertical lines are 95% CIs. Sizes of dark boxes are 
proportional to amount of information. Dashed line: one death from breast 
cancer avoided for every four recurrences avoided. pN0=pathologically 
node-negative. pN+=pathologically node-positive.
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breast-conserving surgery only than for those allocated to 
breast-conserving surgery plus radiotherapy (webappendix 
pp 38–39). Because only 1050 women had pN+ disease in 
these trials, the relevance of prognostic factors and other 
characteristics could not be explored reliably in this 
group (webappendix pp 40–44).
On average, in all the women in these trials, about one 
breast cancer death was avoided by year 15 for every four 
recurrences avoided by year 10 (ﬁ gure 1). For pN+ disease 
and for pN0 disease with large predicted absolute 
recurrence beneﬁ t the observed ratio was slightly larger, 
whereas for pN0 disease with intermediate or lower 
predicted absolute beneﬁ t it was somewhat smaller 
(ﬁ gure 5). However, the departure from linearity was not 
statistically signiﬁ cant (2p=0·11).
Discussion
The overall ﬁ ndings from these trials show that 
radiotherapy after breast-conserving surgery not only 
substantially reduces the risk of recurrence but also 
moderately reduces the risk of death from breast cancer. 
These results suggest that killing microscopic tumour 
foci in the conserved breast with radiotherapy reduces 
the potential for both local recurrence and distant 
metastasis. Both proportional and absolute reductions in 
the annual recurrence rate are largest in the ﬁ rst year but 
the recurrence rate continues to be somewhat lower 
throughout the ﬁ rst decade, whereas the reduction in 
breast cancer death rate becomes deﬁ nite only after the 
ﬁ rst few years and appears to continue into the second 
decade. Non-breast-cancer mortality and the incidence of 
contralateral and other second cancers in these and other 
trials of radiotherapy in early breast cancer will be 
reported elsewhere, but there appeared to be little adverse 
eﬀ ect on 15-year mortality from the aggregate of all 
causes other than breast cancer, so 15-year all-cause 
mortality was reduced by almost as much as would be 
expected from the reduction in breast cancer mortality. 
Previous analyses had shown that in pN0 disease young 
age, large tumour size, and high grade were each strongly 
predictive of the risk of locoregional recurrence and of 
the absolute reduction in that risk with radiotherapy.5 
This report combines the predictive value of these and 
other factors, such as wider tamoxifen use in recent trials. 
Taken together, they account for the fact that the absolute 
recurrence reduction with radiotherapy is lower in the 
more recent postlumpectomy trials (ie, category C trials) 
than in the original postlumpectomy trials (ie, category A 
trials, table 2). However, even for women with pN0 disease 
in the recent low-risk trials the predicted absolute 10-year 
recurrence reduction with radio therapy exceeded 10% in 
most women and exceeded 20% in some women. 
Almost a quarter of women with pN0 disease were in 
trials in which sector resection or quadrantectomy, rather 
than lumpectomy, was undertaken and tamoxifen was not 
trial policy for pN0 disease in any of these trials. Recurrence 
rates were, however, lower than those for women with 
similar characteristics in trials in which lumpectomy was 
performed (ﬁ gure 4). This diﬀ erence accords with the 
ﬁ ndings of the one randomised trial of quadrantectomy 
versus lumpectomy, both with radiotherapy, in 700 women, 
two-thirds of whom were node negative.25 Most of the trials 
of radiotherapy after lumpectomy required negative 
surgical margins for invasive cancer (although not for 
ductal carcinoma in situ). However, pathological techniques 
have become more sensitive since the women entered 
these trials, and some would probably have been positive 
with modern techniques. Therefore, whether the lower 
recurrence rates recorded in trials of radiotherapy in 
women given sector resection or quadrantectomy are 
simply the result of a reduction in the proportion of women 
with positive margins, or whether there is further beneﬁ t 
to be derived from more extensive surgery, is unknown. 
The classiﬁ cation of pN0 disease into three groups 
with large, intermediate, and lower predicted absolute 
recurrence beneﬁ t from radiotherapy was derived from 
the recurrence data in these trials. The classiﬁ cation 
cannot be validated externally and so should not be over-
interpreted. Nevertheless, the size of the diﬀ erence in 
the absolute recurrence reduction between the three 
groups is striking. Furthermore, the 15-year reduction 
in risk of breast cancer death was about as big in 
pN0 disease with large predicted absolute recurrence 
beneﬁ t as it was in pN+ disease, whereas in pN0 disease 
with intermediate or lower predicted recurrence beneﬁ t 
the mortality reduction was smaller and neither diﬀ ered 
signiﬁ cantly from zero. Therefore the number of breast 
cancer deaths avoided per recurrence avoided might be 
more than one in four in pN+ disease and in pN0 disease 
with large predicted absolute recurrence beneﬁ t, and 
less than one in four for women with intermediate or 
lower predicted absolute beneﬁ t (ﬁ gure 5). However, the 
present data do not depart signiﬁ cantly from the one-in-
four relationship.
The main analyses presented are of ﬁ rst recurrence of 
any type rather than, as previously, locoregional 
recurrence as a ﬁ rst event. This diﬀ erence is partly 
because it is now clear that radiotherapy after breast-
conserving surgery reduces breast cancer death, so it 
must also reduce distant recurrence. It is also because 
women with higher risk of locoregional recurrence have 
higher risk of distant recurrence (ie, the probabilities of 
locoregional and of distant recurrence are not statistically 
independent), so valid estimates of the separate eﬀ ects of 
radiotherapy on local and distant recurrence cannot be 
obtained.26,27 These issues are more important at 10 years 
than at 5 years (as presented previously), because more 
distant recurrences occur by 10 years than by 5 years. The 
fact that the proportion of ﬁ rst recurrences that were 
locoregional was much lower in irradiated women than 
in controls does, however, suggest that the main eﬀ ect of 
radiotherapy was to reduce locoregional recurrence, 
whereas the reduction of the breast cancer death rate by a 
sixth suggests that the distant recurrence rate was 
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reduced by at least as much. No analyses have been 
undertaken of recurrences after the ﬁ rst, because they 
are aﬀ ected by treatment policies for the ﬁ rst recurrence, 
and many trials did not record further recurrences. 
Screening, surgery, pathology, radiotherapy, and sys-
temic therapy28,29 have all changed substantially since 
most of the women entered these trials, so the absolute 
recurrence reduction with radiotherapy in future patients 
might diﬀ er greatly from that recorded in these trials. 
Moreover, information about additional risk factors will 
often be available (eg, HER2, gene expression proﬁ le, 
margin status) and a radiotherapy boost may be given.30,31 
Nevertheless, the ﬁ nding that radiotherapy roughly 
halved the recurrence rate after breast-conserving surgery 
in a wide range of patients with very diﬀ erent absolute 
risks (ﬁ gure 3) suggests that it might also roughly halve 
the recurrence rate in future patients given breast-
conserving surgery but who are not comparable with the 
women included in the trials analysed here. If so, then in 
these future patients, a reasonable way to predict the 
absolute recurrence beneﬁ t of radiotherapy would be to 
construct contemporary estimates of the absolute risk of 
ﬁ rst recurrence of any type and to assume that 
radiotherapy will approximately halve it.
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